CD34+ Hematopoietic Progenitor Cell Selection of Bone Marrow Grafts for Autologous Transplantation in Pediatric Patients

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 5, 2007, Pages 608-614

  Kasow, Kimberly A ^a   Sims Poston, Leigh ^a   Eldridge, Paul ^a   Hale, Gregory A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Autologous bone marrow transplantation; CD34+ selection; Isolex ; Lymphoma; Neuroblastoma

Indexed keywords

BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DIMETHYL SULFOXIDE; ETOPOFOS; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; TOPOTECAN;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL COUNT; CELL SELECTION; CHILD; CONTROLLED STUDY; EXPERIENCE; FEASIBILITY STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; MEDICAL RECORD REVIEW; NEUROBLASTOMA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PEDIATRICS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PURIFICATION; SINUS BRADYCARDIA; THROMBOCYTE; WHOLE BODY RADIATION;

ADOLESCENT; ANTIGENS, CD34; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOMAGNETIC SEPARATION; LYMPHOMA, NON-HODGKIN; MALE; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; STEM CELLS; TRANSPLANTATION, AUTOLOGOUS;

EID: 34247094683     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.01.074     Document Type: Article

References (24)

1. Civin C.I., Trischmann T., Kadan N.S., et al. Highly purified CD34-positive cells reconstitute hematopoiesis. J Clin Oncol. 14 (1996) 2224-2233
2. Vogel W., Schedings S., Kanz L., and Brugger W. Clinical applications of CD34(+) peripheral blood progenitor cells (PBPC). Stem Cells 18 (2000) 87-92
3. Chou T., Sano M., Ogura M., et al. Isolation and transplantation of highly purified autologous peripheral CD34+progenitor cells: purging efficacy, hematopoietic reconstitution following high dose chemotherapy in patients with breast cancer: results of a feasibility study in Japan. Breast Cancer 12 (2005) 178-188
4. Kruger W., Gruber M., Hennings S., et al. Purging and haematopoietic progenitor cell selection by CD34+ cell separation. Bone Marrow Transplant. 21 (1998) 665-671
5. + Selection as a stem cell purging strategy for neuroblastoma: preclinical and clinical studies. Med Pediatr Oncol. 35 (2000) 677-682
6. + cells from blood stem cell components using the Baxter Isolex system. Bone Marrow Transplant. 21 (1998) 1253-1262
7. Blystad A.K., Torlakovic E., Holte H., et al. CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD. Cytotherapy 3 (2001) 295-305
8. Roots-Weiss A., Papadimitriou C., Serve H., et al. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems. Bone Marrow Transplant. 19 (1997) 1239-1246
9. Prince H.M., Bashford J., Wall D., et al. Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy. Cytotherapy 4 (2002) 137-145
10. Preti R.A., Lazarus H.M., Winter J., et al. Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer. Cytotherapy 3 (2001) 85-95
11. Handgretinger R., Lang P., Schumm M., et al. Isolation and transplantation of autologous peripheral CD34+ progenitor cells highly purified by magnetic-activated cell sorting. Bone Marrow Transplant. 21 (1998) 987-993
12. Kajiume T., Kawano Y., Takaue Y., et al. New consecutive high-dose chemotherapy modality with fractionated blood stem cell support in the treatment of high-risk pediatric solid tumors: a feasibility study. Bone Marrow Transplant 21 (1998) 147-151
13. Hale G., Bowman L., Stewart C., et al. Cyclophosphamide and targeted dose topotecan with autologous hematopoietic stem cell rescue for solid tumors. Proc Am Soc Clin Oncol. 23 (2004) 803a
14. Hale G.A., Horwitz E., Leung W., et al. CD133+ Hematopoietic cells successfully reconstitute hematopoiesis following autologous peripheral blood stem cell transplantation. Blood 104 (2004) 130a
15. National Cancer Institute. Common toxicity criteria, version 2.0 (CTC) (1999) Bethesda, MD
16. O'Donnell P.V., Myers B., Edwards J., et al. CD 34 selection using three immunoselection devices: comparison of T-cell depleted allografts. Cytotherapy 3 (2001) 483-488
17. Watts M.J., Somervaille T.C., Ings S.J., et al. Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices. Br J Haematol. 118 (2002) 117-123
18. Vose J.M., Sharp G., Chan W.C., et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol. 20 (2002) 2344-2352
19. Vicent M.G., Madero L., Chamorro l., et al. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies. Haematologica 86 (2001) 1087-1094
20. + progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): result of Japanese phase II study. Bone Marrow Transplant 35 (2005) 479-487
21. + peripheral blood stem cells using the Baxter Isolex 300i. J Hematother Stem Cell Res. 11 (2002) 719-730
22. Humpe A., Riggert J., Wolf C., et al. Successful transplantation and engraftment of peripheral blood stem cells after cryopreservation, positive and negative purging procedures, and a second cryopreservation cycle. Ann Hematol. 80 (2001) 109-112
23. + cells: factors influencing component purity and yield. Transfusion 40 (2000) 507-512
24. Brenner M.K., Rill D.R., Moen R.C., et al. Gene marking and autologous bone marrow transplantation. Ann N Y Acad Sci. 716 (1994) 204-214